Skip to content
The Kids Research Institute Australia logo
Donate

Search

Dedicated paediatric Outpatient Parenteral Antimicrobial Therapy medical support: a pre-post observational study

The introduction of a formal medical team to Hospital in the Home (HiTH) demonstrated a positive clinical impact on Parenteral Antimicrobial Therapy (OPAT) patients' outcomes.

Repeated vaccination does not appear to impact upon influenza vaccine effectiveness against hospitalization with confirmed influenza

These findings reinforce current recommendations for annual influenza vaccination, particularly those at greatest risk of influenza disease.

Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity

There has been a coordinated effort from academic institutions and the PI to identify biomarkers that can predict immune checkpoint blockade response in cancer.

Birth outcomes for Australian mother-infant pairs who received an influenza vaccine during pregnancy, 2012-2014: The FluMum study

We assessed the safety of receiving an influenza vaccination during any trimester of pregnancy with respect to preterm births and infant birthweight.

Influenza epidemiology in patients admitted to sentinel Australian hospitals in 2015: the Influenza Complications Alert Network

This report summarises the epidemiology of hospitalisations with laboratory-confirmed influenza during the 2015 influenza season

An observational study of febrile seizures: The importance of viral infection and immunization

Determine the frequency of detection of specific viral pathogens in children with febrile seizures

Biofilm forming potential and antimicrobial susceptibility of newly emerged Western Australian Bordetella pertussis clinical isolates

Isobaric tags for relative and absolute quantitation (iTRAQ)-based proteomic analysis revealed significant differences in protein expression in B. pertussis biofilms

Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years

In women older than 25 years, the HPV 16/18 vaccine continues to protect against infections, cytological abnormalities, and lesions associated with HPV 16/18